[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE85080T1 - Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. - Google Patents

Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.

Info

Publication number
ATE85080T1
ATE85080T1 AT85301037T AT85301037T ATE85080T1 AT E85080 T1 ATE85080 T1 AT E85080T1 AT 85301037 T AT85301037 T AT 85301037T AT 85301037 T AT85301037 T AT 85301037T AT E85080 T1 ATE85080 T1 AT E85080T1
Authority
AT
Austria
Prior art keywords
fragments
alpha
tgf
growth factor
human
Prior art date
Application number
AT85301037T
Other languages
English (en)
Inventor
Rik Michel Andre Derynck
David Vannorman Goeddel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE85080T1 publication Critical patent/ATE85080T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT85301037T 1984-02-17 1985-02-15 Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. ATE85080T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58174384A 1984-02-17 1984-02-17
EP85301037A EP0154434B1 (de) 1984-02-17 1985-02-15 Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
US06/695,494 US4742003A (en) 1984-02-17 1985-05-14 Human transforming growth factor

Publications (1)

Publication Number Publication Date
ATE85080T1 true ATE85080T1 (de) 1993-02-15

Family

ID=27078409

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85301037T ATE85080T1 (de) 1984-02-17 1985-02-15 Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.

Country Status (5)

Country Link
US (1) US4742003A (de)
EP (1) EP0154434B1 (de)
AT (1) ATE85080T1 (de)
CA (1) CA1341227C (de)
DE (1) DE3587022T2 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
AU5249786A (en) * 1985-01-29 1986-08-07 Oncogen Wound healing compositions
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
WO1986006076A1 (en) * 1985-04-18 1986-10-23 Biotechnology Australia Pty. Ltd. Recombinant inhibin
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US5130300A (en) * 1986-03-07 1992-07-14 Monsanto Company Method for enhancing growth of mammary parenchyma
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US6994988B1 (en) * 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
EP0339905A3 (de) * 1988-04-25 1991-05-08 Ethicon, Inc. Wachstumfaktoren und Retinoiden enthaltende Wundheilungzusammensetzungen
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5256644A (en) * 1988-05-20 1993-10-26 Institute Of Molecular Biology, Inc. Wound healing using IGF-II and TGF
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5304541A (en) * 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
US5246104A (en) * 1989-08-01 1993-09-21 United States Surgical Corporation Molded suture retainer
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US5849694A (en) * 1990-07-16 1998-12-15 Synenki; Richard M. Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof
US5360790A (en) * 1990-12-11 1994-11-01 The Regents Of The University Of Michigan Method and formulations for the therapy of acute renal failure
US20040175795A1 (en) * 1991-09-20 2004-09-09 Amgen Inc. Glial derived neurotrophic factor
DK0610254T3 (da) 1991-09-20 2005-01-10 Amgen Inc Glial-afledt neurotrofisk faktor
AU3178893A (en) * 1991-11-15 1993-06-15 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
KR950704485A (ko) * 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
JPH11506908A (ja) * 1995-05-19 1999-06-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド トランスフォーミング増殖因子αＨＩＩ
EP1881069A1 (de) * 1995-05-19 2008-01-23 Human Genome Sciences, Inc. Transformierender Wachstumsfaktor alpha HII
US6410506B1 (en) 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US5858669A (en) * 1996-09-13 1999-01-12 The Trustees Of Columbia University In The City Of New York Beclin, a novel bcl-2 interacting gene near BRCA1 on chromosome 17q21 and methods of use
WO2000034310A1 (en) * 1998-12-10 2000-06-15 Vanderbilt University Purified and isolated serine-threonine kinase receptors associated protein
US6770458B1 (en) 1998-12-10 2004-08-03 Vanderbilt University Purified and isolated serine-threonine kinase receptors associated protein and use of same in the modulation of the biological activity of TGF-β
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
US6486122B1 (en) * 1999-04-26 2002-11-26 Stem Cell Pharmaceuticals, Inc. Methods of increasing body weight in a subject by administering TGF-α
IL147127A0 (en) * 1999-06-22 2002-08-14 Res Dev Foundation Method to enhance wound healing and enhanced wound coverage material
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6677307B2 (en) 1999-08-19 2004-01-13 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
WO2002024148A2 (en) * 2000-09-22 2002-03-28 Stem Cell Pharmaceuticals Inc. Method or treatment of tumors using transforming growth factor-alpha
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
US7994159B2 (en) * 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CN101309930A (zh) * 2003-08-19 2008-11-19 阿戈斯生物科技有限公司 ErbB配体的剪接变体、其组合物及其用途
JP4303726B2 (ja) * 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
EP1765981A4 (de) * 2004-06-11 2007-09-12 Victorian Tissue Engineering C Gewebematerial und aus muskel gewonnene matrix
DE602005013990D1 (de) * 2004-09-17 2009-05-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
WO2007052850A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
EP2044939A1 (de) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutisches mittel gegen leberfibrose
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
JP5319306B2 (ja) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
JP5606916B2 (ja) 2007-10-19 2014-10-15 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2248804A4 (de) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd Kombinationsverwendung eines angiogenesehemmers und taxans
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3825305A1 (de) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Verfahren zur herstellung von lenvatinib
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4358586A (en) * 1980-12-23 1982-11-09 Harvey Rubin Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IE57724B1 (en) * 1983-05-09 1993-03-24 Todaro George Joseph Biologically active polypeptides
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985002198A1 (en) * 1983-11-01 1985-05-23 Amgen Microbial expression of type i transforming growth factor, polypeptide analogs thereof and hybrid egf/tgf polypeptides

Also Published As

Publication number Publication date
DE3587022T2 (de) 1993-06-17
CA1341227C (en) 2001-05-15
EP0154434B1 (de) 1993-01-27
DE3587022D1 (de) 1993-03-11
US4742003A (en) 1988-05-03
EP0154434A1 (de) 1985-09-11

Similar Documents

Publication Publication Date Title
ATE85080T1 (de) Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
ATE91629T1 (de) Adhesin-antigene, antikoerper und dns-fragmente die das antigen kodieren, verfahren und mittel zur diagnose und immunisierung, usw.
ATE260971T1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE330002T1 (de) Verfahren zur herstellung von membranvesikeln
ES2085245T1 (es) Procedimiento para aislar acido nucleico.
KR880701288A (ko) M-csf의 제법
Fullmer et al. Human gingival collagenase: purification, molecular weight, and inhibitor studies
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
Rollof et al. Lipolytic activity of Staphylococcus aureus strains from disseminated and localized infections
ATE121424T1 (de) Hpth-fragment-(1-37), seine herstellung, dieses enthaltende arzneimittel und seine verwendung.
DE3877669D1 (de) Verfahren zur kristallmorphologischen blut- und harnanalyse, zur fruehdiagnose und zur herstellung von arzneimitteln.
ES398962A1 (es) Un procedimiento para la preparacion de una composicion de enzima.
AU4492393A (en) Bone-related carboxypeptidase-like protein and process for its production
CN109320591B (zh) 一种多肽oa-gl12及其应用
CN106190946A (zh) 一种用于干细胞扩增的培养基
DE68924222D1 (de) Megakaryocytopoietin, seine Herstellung und Benutzung.
Jörgensen et al. Serogenetic investigations on malignant melanomas with reference to the incidence of AB0 system, Rh system, Gm, Inv, Hp and Gc systems
Fojo et al. The isolation and characterization of a colony stimulating factor from human lung
AU654651B2 (en) Method of preparing lysozyme dimers
Seligmann et al. Immunological Studies in Familial β 2-Macroglobulinaemias.
EP0516845A4 (de) Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung.
RU2288729C2 (ru) Способ выделения коллагена из костной ткани сельскохозяйственных животных
Philipov et al. A clinical study on the therapeutic effect of bee products on trophic chronic varicoses ulcerations of the inferior limbs
CN116115644A (zh) 一种利用外泌体促进创面修复的药剂及其制备方法
Hijmans et al. Further observations on L forms of alpha-hemolytic Streptococci.

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time